Venaxis, Inc. operates as a biomedical company in the United States. Its research and development activities primarily focus on a human acute appendicitis blood-based test. The company s lead product candidate includes APPY1, a blood-based diagnostic test designed to aid in the evaluation of patients presenting signs and symptoms of acute appendicitis for physicians to diagnose acute appendicitis in children and adolescents with symptoms of the disease. It is also developing animal health products, including cattle reproduction products that comprise BoviPure-LH and BoviPure-FSH; and equine reproduction products, which consist of EquiPure-FSH and EquiPure-LH. The company was formerly known as AspenBio Pharma, Inc. and changed its name to Venaxis, Inc. in December 2012. Venaxis, Inc. was founded in 2000 and is based in Castle Rock, Colorado.
Symbol:
Current Quote
last: 1.66
bid:
ask:
volume: 40948

as of (GMT): 2013-05-21 15:59:00
*Quotes delayed by 20min.
Stock Exchange / Market : NASDAQ
 Off list - 92 consecutive market days. Off list as of 02/25/2008 through 05/20/2013 

3 Month
APPY 3 Month

6 Month
APPY 6 Month

1 Year
APPY 1 Year

Borrow Rates (per share)